Archives

Proprietary immuno-oncology approach harnesses autologous dendritic cell therapy

`s-Hertogenbosch,
The Netherlands, 21 May 2019. Amphera B.V., an advanced-clinical-stage
biotechnology company developing dendritic cell therapies to treat cancer,
announces that it has recruited the first patients to a phase II study of
MesoPher to treat pancreatic cancer.

REACtiVe
(Rotterdam pancrEAtic cancer Vaccination trial) is an open-label phase II study
in 10 adult patients with surgically resected pancreatic cancer who have
received adjuvant standard of care treatment.

MesoPher, a personalised immuno-oncology cell therapy, is comprised
of autologous dendritic cells loaded with PheraLys, Amphera’s proprietary
allogeneic lysate of mesothelioma cell lines. PheraLys, first developed for
mesothelioma, contains a broad-spectrum of tumour-associated antigens,
many of

Amphera is one of the ten winners of the Academic Startup Competition. This was announced by a professional jury in Amsterdam in the presence of State Secretary for Economic Affairs and Climate, Mona Keijzer.

As a result of the selection, Amphera will be able to pitch at the Global Entrepreneurship Summit (GES) and will be offered a trip to Silicon Valley by the Ministry of Economic Affairs and Climate Change. The GES will give Amphera the opportunity to learn how to scale up their innovation faster and take the step from startup to scale-up.

The 10 winners of the Academic Startup

New data suggests high level of disease control possible with combination of dendritic cell therapy and PD-1/PD-L1 checkpoint inhibitors

`s-Hertogenbosch, The Netherlands, 3 April 2019. Amphera B.V., an advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer, presented data from patients that received a combination of its dendritic cell therapy product MesoPher with marketed checkpoint inhibitors, to treat mesothelioma. The data was presented at the AACR Annual Meeting 2019 in Atlanta, Georgia.

Dendritic Cells (DCs) capture, process, and present antigens to the immune system. However, mesothelioma suppresses the differentiation, maturation and therefore immuno-stimulatory function of

Proprietary immuno-oncology approach harnesses
autologous dendritic cell therapy to treat an orphan-designated cancer

`s-Hertogenbosch,
The Netherlands, 18 March 2019.
Amphera B.V., an advanced-clinical-stage biotechnology company developing
dendritic cell therapies to treat cancer, announces that it has recruited the
first patients to its pivotal phase II/III study of MesoPher to treat pleural
mesothelioma, a rare cancer of the lining of the lungs.

DENIM (DENdritic cell Immunotherapy for Mesothelioma) is
an open-label, randomised, phase II/III study in 230 adults with pleural
mesothelioma, to assess the efficacy and anti-tumour activity of MesoPher as
maintenance treatment after chemotherapy. Patients in Arm A will receive 3
bi-weekly injections of MesoPher with best supportive care, plus

On March 15, 2018 prof Joachim Aerts MD of Erasmus MC received a “Parel” (Pearl) from ZonMW for his research on dendritic cell immunotherapy MesoPher for mesothelioma. ZonMW is the The Netherlands Organisation for Health Research and Development.

The Dutch patient association, Asbestslachtoffers Vereniging Nederland (AVN) and Amphera received an “Oorkonde” (certificate) for their contributions to this study.

Amphera truly appreciates the Oorkonde, as it is an acknowledgement of the productive collaboration between an academic hospital, a patient association and a small biotech company.

More information (in Dutch) can be found on: https://www.zonmw.nl/nl/actueel/nieuws/detail/item/zonmw-parel-voor-afweerreactie-tegen-asbestkanker

On March 30 2018, the participants in the DENIM study held a consortium meeting at CHRU Lille in France. Prof Arnauld Scherpereel and his team hosted the meeting. All topics were discussed in a very constructive atmosphere.

On World Cancer Day February 4 2018, KWF – Dutch Cancer Society – organized several activities to increase the awareness about cancer and its impact. Prof Joachim Aerts was one of the guests in live programs on the radio and internet. In his contribution, he discussed the results of the phase I/II studies with dendritic cell therapy in mesothelioma. (prof Aerts starts on 13’45” – Dutch only)

Amphera B.V. today announces the positive results of the clinical study with MesoPher in patients with malignant mesothelioma.

Amphera B.V., a spin-off company of Erasmus MC, develops dendritic cell immunotherapies for malignant mesothelioma and other cancers.

Malignant mesothelioma is a fatal cancer caused by inhalation of asbestos fibers. Researchers of Erasmus MC, The Netherlands have developed an innovative immunotherapy for mesothelioma. This new therapy, MesoPher activates the patient’s own immune system against the tumour. MesoPher consists of autologous dendritic cells loaded with allogeneic tumour cell lysate.

Amphera B.V. performed a clinical study with this new approach. Prof Joachim Aerts MD

On June 20, 2014 we are moving. On this day it might be difficult to contact us. Our sincere apologies for this inconvenience. We hope and trust that on Monday, June 23 we will be fully operational again.

The new address of Amphera is:

Onderwijsboulevard 225 (which was 219)

5223 DE ‘s-Hertogenbosch

Our mailing address, email addresses and general telephone number will not change.

On May 6, 2014 the FDA – the U.S. Food & Drug Administration – granted Amphera’s treatment of malignant mesothelioma Orphan Designation.